Drugs for the treatment of central diabetes insipidus: historical background and modern opportunities
https://doi.org/10.14341/omet2017117-23
Abstract
Central diabetes insipidus is a severe disease with disturbance of arginine vasopressin secretion, which leads to excretion of large amounts of hypotonic urine. The polyuria-polydipsia syndrome is essential as a clinical presentation and high impact condition. Desmopressin, a synthetic analog of arginine vasopressin, is used to compensate a water-electrolyte balance is available in forms of tablets and intranasal spray. Free drug choice is obligated for proper treatment.
About the Authors
Dar'ya S. MikhaylovaEndocrinology Research Centre
Russian Federation
postgraduate student
Competing Interests:
конфликт интересов отсутствует
Ekaterina A. Pigarova
Endocrinology Research Centre
Russian Federation
PhD
Competing Interests:
конфликт интересов отсутствует
Larisa K. Dzeranova
Endocrinology Research Centre
Russian Federation
ScD
Competing Interests:
конфликт интересов отсутствует
References
1. Abraham MB, Rao S, Price G, Choong CS. Efficacy of Hydrochlorothiazide and low renal solute feed in Neonatal Central Diabetes Insipidus with transition to Oral Desmopressin in early infancy. International Journal of Pediatric Endocrinology. 2014;2014(1):11. doi: 10.1186/1687-9856-2014-11.
2. Asplund, Sundberg, Bengtsson. Oral desmopressin for nocturnal polyuria in elderly subjects: a double-blind, placebo-controlled randomized exploratory study. BJU International. 2001;83(6):591-595. doi: 10.1046/j.1464-410x.1999.00012.x.
3. Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia Associated with Carbamazepine and Oxcarbazepine Therapy: A Review. Epilepsia. 1994;35(1):181-188. doi: 10.1111/j.1528-1157.1994.tb02930.x.
4. Bailey P. Experimental Diabetes Insipidus. Archives of Internal Medicine. 1921;28(6):773. doi: 10.1001/archinte.1921.00100180091006.
5. de Braganca AC, Moyses ZP, Magaldi AJ. Carbamazepine can induce kidney water absorption by increasing aquaporin 2 expression. Nephrology Dialysis Transplantation. 2010;25(12):3840-3845. doi: 10.1093/ndt/gfq317.
6. Camus J, Roussy G. Experimental Researches on the Pituitary Body Diabetes Insipidus, Glycosuria and Those Dystrophies Considered as Hypophyseal in Origin*. Endocrinology. 1920;4(4):507-522. doi: 10.1210/endo-4-4-507.
7. Cannon JF. Diabetes Insipidus. A.M.A. Archives of Internal Medicine. 1955;96(2):215. doi: 10.1001/archinte.1955.00250130089012.
8. Saifan C, Nasr R, Mehta S, et al. Diabetes Insipidus: A Challenging Diagnosis with New Drug Therapies. ISRN Nephrology. 2013;2013:1-7. doi: 10.5402/2013/797620.
9. Maria L. Chiozza RdG. Italian Multicentre Open Trial on DDAVP Spray in Nocturnal Enuresis. Scandinavian Journal of Urology and Nephrology. 2009;33(1):42-48. doi: 10.1080/003655999750016267.
10. Coculescu M, Antipa C, Cucu C. Effects of DDAVP in cranial diabetes insipidus as compared to other antidiuretic drugs. Endocrinologie. 1977;15(4):275-281.
11. Crawford B, Skeath M, Whippy A. Kaiser Permanente Northern California sepsis mortality reduction initiative. Critical Care. 2012;16(Suppl 3):P12. doi: 10.1186/cc11699.
12. Eknoyan G. A History of Diabetes Insipidus: Paving the Road to Internal Water Balance. American Journal of Kidney Diseases. 2010;56(6):1175-1183. doi: 10.1053/j.ajkd.2010.08.002.
13. Eknoyan G, Nagy J. A history of diabetes mellitus or how a disease of the kidneys evolved into a kidney disease. Advances in Chronic Kidney Disease. 2005;12(2):223-229. doi: 10.1053/j.ackd.2005.01.002.
14. Friedman FM, Weiss JP. Desmopressin in the treatment of nocturia: clinical evidence and experience. Therapeutic Advances in Urology. 2013;5(6):310-317. doi: 10.1177/1756287213502116.
15. Farini F. About diabetes insipidus and hypophysiotherapy. Wien Klin Wochenschr. 1913;26:1867.
16. Forssman HH. On hereditary diabetes insipidus. Acta Medica Scandinavica. 1945;121.
17. Frank J. Classis V, Ordo I. Genus II. De Curandis Hominum Morbis. 1832
18. García Castaño A, Pérez de Nanclares G, Madariaga L, et al. Novel mutations associated with nephrogenic diabetes insipidus. A clinical-genetic study. European Journal of Pediatrics. 2015;174(10):1373-1385. doi: 10.1007/s00431-015-2534-4.
19. Harris AS, Hedner P, Vilhardt H. Nasal administration of desmopressin by spray and drops. Journal of Pharmacy and Pharmacology. 1987;39(11):932-934. doi: 10.1111/j.2042-7158.1987.tb03131.x.
20. Henry DA, Lawson DH, Reavey P, Renfrew S. Hyponatraemia during carbamazepine treatment. Bmj. 1977;1(6053):83-84. doi: 10.1136/bmj.1.6053.83-a.
21. Hocken AG, Longson D. Reduction of free water clearance by chlorporpamide. Bmj. 1968;1(5588):355-356. doi: 10.1136/bmj.1.5588.355.
22. Di Iorgi N, Napoli F, Allegri AEM, et al. Diabetes Insipidus • Diagnosis and Management. Hormone Research in Paediatrics. 2012;77(2):69-84. doi: 10.1159/000336333.
23. Juul KV, Bichet DG, Nielsen S, Norgaard JP. The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors. AJP: Renal Physiology. 2014;306(9):F931-F940. doi: 10.1152/ajprenal.00604.2013.
24. Kamiyama T, Iseki K, Kawazoe N, et al. Carbamazepine-Induced Hyponatremia in a Patient with Partial Central Diabetes insipidus. Nephron. 2008;64(1):142-145. doi: 10.1159/000187295.
25. Kauli R, Laron Z. A vasopressin analogue in treatment of diabetes insipidus. Archives of Disease in Childhood. 1974;49(6):482-485. doi: 10.1136/adc.49.6.482.
26. Kayamori K, Fujitani J, Kawachi S. Efficacy of intranasal desmopressin for the treatment of nocturnal polyuria in the elderly females. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics. 2014;51(1):85-88. doi: 10.3143/geriatrics.51.85.
27. Kocak M, Karademir BM, Tetiker T. Antidiuretic effect of indapamide in central diabetes insipidus. Acta Endocrinol (Copenh). 1990;123(6):657-660.
28. Kumar S, Behera NC, Sarkar D, et al. A comparative assessment of the clinical efficacy of intranasal desmopressin spray and diclofenac in the treatment of renal colic. Urological Research. 2011;39(5):397-400. doi: 10.1007/s00240-010-0354-6.
29. Lacombe U. De la polydipsia. J Med Chir. 1841;7:305-23.
30. Lam KSL, Wat MS, Choi KL, et al. Pharmacokinetics, pharmacodynamics, long-term efficacy and safety of oral 1-deamino-8-d-arginine vasopressin in adult patients with central diabetes insipidus. British Journal of Clinical Pharmacology. 2003;42(3):379-385. doi: 10.1046/j.1365-2125.1996.39914.x.
31. de Lange C. Ueber erblichen diabetes insipidus Jahrbuch fuer Kinderheilkunde. 1935;145:135.
32. Magnus RS. Effects of post-pituitary extracts. Journal of Physiology. 1901;12:32-38.
33. Makaryus AN, McFarlane SI. Diabetes insipidus: diagnosis and treatment of a complex disease. Cleveland Clinic Journal of Medicine. 2006;73(1):65-71. doi: 10.3949/ccjm.73.1.65.
34. MaraÑ=N G. Diabetes Insipidus as a Hypopituitary Syndrome. Endocrinology. 1921;5(2):159-173. doi: 10.1210/endo-5-2-159.
35. McIlraith C. Notes on Some Cases of Diabetes Insipidus with Marked Family and Hereditary Tendencies. The Lancet. 1892;140(3605):767-768. doi: 10.1016/s0140-6736(01)87712-6.
36. Meinders AE, Cejka V, Robertson GL. The Antidiuretic Action of Carbamazepine in Man. Clinical Science. 1974;47(4):289-299. doi: 10.1042/cs0470289.
37. Moses AM, Howanitz J, Gemert MV, Miller M. Clofibrate-Induced Antidiuresis. Journal of Clinical Investigation. 1973;52(3):535-542. doi: 10.1172/jci107213.
38. Motzfeldt K. Diabetes Insipidus. Endocrinology. 1918;2(2):112-121. doi: 10.1210/endo-2-2-112.
39. Al Nofal A, Lteif A. Thiazide Diuretics in the Management of Young Children with Central Diabetes Insipidus. The Journal of Pediatrics. 2015;167(3):658-661. doi: 10.1016/j.jpeds.2015.06.002.
40. Pokracki FJ, Robinson AG, Seif SM. Chlorpropamide effect: Measurement of neurophysin and vasopressin in humans and rats. Metabolism. 1981;30(1):72-78. doi: 10.1016/0026-0495(81)90222-5.
41. Qureshi S, Galiveeti S, Bichet DG, Roth J. Diabetes Insipidus: Celebrating a Century of Vasopressin Therapy. Endocrinology. 2014;155(12):4605-4621. doi: 10.1210/en.2014-1385.
42. Ranson SW Some Functions of the Hypothalamus: Harvey Lecture, December 17, 1936. Bulletin of the New York Academy of Medicine. 1937;13(5):241-71
43. Richardson DW, Robinson AG. Desmopressin. Ann Intern Med. 1985;103(2):228-239.
44. Robinson AG. DDAVP in the Treatment of Central Diabetes Insipidus. New England Journal of Medicine. 1976;294(10):507-511. doi: 10.1056/nejm197603042941001.
45. Robinson AG, Verbalis JG. Diabetes insipidus. Curr Ther Endocrinol Metab. 1997;6:1-7.
46. Robertson GL. Diabetes insipidus. Endocrinol Metab Clin North Am. 1995;24(3):549-572.
47. Saifan C, Nasr R, Mehta S, et al. Diabetes Insipidus: A Challenging Diagnosis with New Drug Therapies. ISRN Nephrology. 2013;2013:1-7. doi: 10.5402/2013/797620.
48. Chirman SB, Kinsell LW. Diabetes Insipidus. Treatment with 8-Lysine Vasopressin in a Nasal Spray. Calif Med. 1964;101:1-3. PMC1515569.
49. Malve H, Kalra S, Zargar A, et al. Diabetes insipidus: The other diabetes. Indian Journal of Endocrinology and Metabolism. 2016;20(1):9. doi: 10.4103/2230-8210.172273.
50. Sarma KV. Algorithmic approach for the diagnosis of polyuria. In: Muruganathan A, editor. Medicine Update. Vol. 23. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2013. pp. 311–3.
51. Short JR, Isles A. Diabetes insipidus treated by DDAVP. Med J Aust. 1976;1(20):756-757.
52. Du Vigneaud V. Hormones of the posterior pituitary gland: oxytocin and vasopressin. Harvey lectures 1954-1955;50:1-26.
53. Von den Velden R. The kidney effects of hypophysis extracts in humans. Berl Klin Wochenschr. 1913;50:2083.
54. Kathleen DW, Martine C, Ann DG, et al. Desmopressin Lyophilisate for the Treatment of Central Diabetes Insipidus: First Experience in Very Young Infants. International Journal of Endocrinology and Metabolism. 2014;12(4). doi: 10.5812/ijem.16120.
55. Wales JK. Mode of action of chlorpropamide in the treatment of diabetes insipidus. Proc R Soc Med. 1971;64(10):1070-1071. PMC1812776.
56. Waring AJK, Tappan V. A congenital defect of water metabolism. American Journal of Diseases of Children. 1945;69:323-4.
57. Williams RH, Henry C. Nephrogenic Diabetes Insipidus: Transmitted by Females and Appearing during Infancy in Males. Annals of Internal Medicine. 1947;27(1):84. doi: 10.7326/0003-4819-27-1-84.
58. Kataoka Y, Nishida S, Hirakawa A, et al. Comparison of incidence of hyponatremia between intranasal and oral desmopressin in patients with central diabetes insipidus. Endocrine Journal. 2015;62(2):195-200. doi: 10.1507/endocrj.EJ14-0368.
59. Дзеранова Л.К, Пигарова Е.А. Несахарный диабет. Национальное руководство: «Эндокринология»/ Под ред. Дедова И.И., Мельниченко Г.А.. 2 издание, переработанное и дополненное. – М.: ГЭОТАР-Медиа; 2016. с. 804-809. [Dzeranova LK Pigarova EA. Nesakharnyy diabet. In: Dedov II, Melnichenko GA, editors. Natsional'noe rukovodstvo: «Endokrinologiya». Moscow: GEOTAR-Media; 2016. p. 804-809. (In Russ.)]
60. Генри М. Кроненберг, Шломо Мелмед, Кеннет С / Полонски К., П. Рид Ларсен. Эндокринология по Вильямсу. Нейроэндокринология. – М.: Рид Элсивер. – 2010. – С. 401-418. [Genri M. Kronenberg, Shlomo Melmed, Kennet S. Ed by Polonski K, P. Rid Larsen. Endokrinologiya po Vil'yamsu. Neyroendokrinologiya, Moscow: Rid Elsiver; 2010. p.401-418. (In Russ.)]
61. Мазеркина Н. А. Препарат вазомирин в терапии центрального несахарного диабета у детей // Фарматека. – 2014. – №. 16. – С. 86-90. [Mazerkina N. Preparat vazomirin v terapii tsentral'nogo nesakharnogo diabeta u detey. Farmateka. 2014(16):86-90.]
62. Пигарова Е.А. Заболевания нейрогипофиза. Клиническая нейроэндокринология. / Под ред. Дедова И.И.. – М.: УП «Принт», 2011. [Pigarova E. Zabolevaniya neyrogipofiza. Klinicheskaya neyroendokrinologiya. Ed by Dedov II). Moscow:: UP Print. 2011. (In Russ.)]
63. Пигарова Е.А., Дзеранова Л.К. Диагностика и лечение центрального несахарного диабета // Ожирение и метаболизм. – 2014. – Т. 11. – №4. – C. 48-55. [Pigarova EA, Dzeranova LK. Diagnosis and treatment of central diabetes insipidus. Obesity and metabolism. 2014;11(4):48-55. (In Russ.)] doi: 10.14341/omet2014448-55
64. Индивидуализация терапии центрального несахарного диабета: клинический случай применения препарата «Пресайнекс» // Ожирение и метаболизм. – 2010. – Т. 7. – №3. – C. 39-41. [Pigarova EA, Dzeranova LK, Rozhinskaya LY. Individualizatsiya terapii tsentral'nogo nesakharnogo diabeta: klinicheskiy sluchay primeneniya preparata «Presayneks». Obesity and metabolism. 2010;7(3):39-41. (In Russ.)] doi: 10.14341/2071-8713-4983
65. Пигарова Е. А., Дзеранова Л. К., Рожинская Л. Я. Клинический случай применения препарата пресайнекс у пациентки с центральным несахарным диабетом //Русский медицинский журнал. – 2011. – Т. 19. – №. 27. – C. 1714. [Pigarova EA, Dzeranova LK, Rozhinskaya LY. Klinicheskiy sluchay primeneniya preparata presayneks u patsientki s tsentral'nym nesakharnym diabetom. Russkiy meditsinskiy zhurnal. 2011;19(27):1714. (In Russ.)]
66. Пигарова Е. А., Дзеранова Л. К., Рожинская Л. Я. Клинический случай применения пресайнекса у пациента с центральным несахарным диабетом вследствие гистиоцитоза Лангерганса //Эффективная фармакотерапия. – 2011. – №. 46. – С. 60-65. [Pigarova E, Dzeranova L, Rozhinskaya L. Klinicheskiy sluchay primeneniya presayneksa u patsienta s tsentral'nym nesakharnym diabetom vsledstvie gistiotsitoza Langergansa. Effektivnaya farmakoterapiya. 2011;(46):60-65. (In Russ.)]
67. Пигарова Е.А., Рожинская Л.Я. Лечение центральной формы несахарного диабета вследствие нейросаркоидоза. // Эффективная фармакотерапия. – 2015. – № 7. – C. 21-26. [[Pigarova EA, Rozhinskaya LYa. Lechenie tsentral'noy formy nesakharnogo diabeta vsledstvie neyrosarkoidoza. Effektivnaya farmakoterapiya. 2015;(7):21-26. (In Russ.)]
Supplementary files
|
|
1. Рис. 1. Механизм антидиуретического действия АВП. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(42KB)
|
Indexing metadata ▾ | |
Review
For citations:
Mikhaylova D.S., Pigarova E.A., Dzeranova L.K. Drugs for the treatment of central diabetes insipidus: historical background and modern opportunities. Obesity and metabolism. 2017;14(1):17-23. (In Russ.) https://doi.org/10.14341/omet2017117-23
Views:
22693
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
